文献速递临床试验与 GCP流行病学与生物统计

去处方抗胆碱能药物以保护大脑健康:通过去处方降低痴呆风险(R2D2):一项随机临床试验的研究方案

Deprescribing anticholinergics to preserve brain health: reducing the risk of dementia through deprescribing (R2D2): study protocol for a randomized clinical trial.
PubMed 文献 · Trials · 2024-11-22

R2D2试验是一项整群随机临床试验,计划纳入344名65岁及以上、近期使用强抗胆碱能药物的初级保健老年人,比较抗胆碱能药物去处方干预与常规照护对认知和安全性的影响。主要结局为涵盖执行功能、语言和记忆的复合认知测量,每6个月评估一次至2年,由盲法评估员完成。该试验旨在以前瞻性随机设计检验抗胆碱能药物与认知之间的潜在因果关系。

要点

  • R2D2试验计划纳入344名65岁及以上初级保健老年人,以初级保健医生为单位整群随机分组。
  • 主要结局为包括执行功能、语言和记忆的复合认知测量,每6个月评估一次至2年。
  • 该试验旨在以前瞻性随机设计检验抗胆碱能药物与认知之间的潜在因果关系。

核心结论

  • R2D2试验将是在初级保健老年人中检验抗胆碱能特异性去处方干预对认知影响的最大、最长前瞻性随机试验。
  • 结果可能影响去处方方法学,并为抗胆碱能药物与认知之间的关系提供新见解。

研究设计与样本

  • 整群随机临床试验,在初级保健老年人中评估抗胆碱能药物去处方干预与常规照护对认知和安全性结局的影响。
  • 计划纳入344名参与者,以初级保健医生为单位进行整群随机分组以避免污染。
  • 纳入标准为65岁及以上、在大印第安纳波利斯地区接受初级保健、过去2周内使用强抗胆碱能药物或过去一年内有高风险暴露证据者。
  • 排除阿尔茨海默病或相关痴呆诊断或严重精神疾病者。
  • 由盲法结局评估员每6个月完成一次结局评估,直至2年。

主要发现

  • 主要结局为包括执行认知功能、语言和记忆域的复合认知测量。
  • 次要结局包括患者报告的疼痛强度、抑郁、焦虑、睡眠障碍和健康相关生活质量测量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Older adults commonly experience chronic medical conditions and are at risk of cognitive impairment as a result of age, chronic comorbidity, and medications prescribed to manage multiple chronic conditions. Anticholinergic medications are common treatments for chronic conditions and have been repeatedly associated with poor cognitive outcomes, including delirium and dementia, in epidemiologic studies. However, no study has definitively evaluated the causal relationship between anticholinergics and cognition in a randomized controlled trial design. Utilizing our prior experience in deprescribing anticholinergic medications in various clinical environments, we designed an outpatient deprescribing intervention to prospectively test the potential causal relationship between anticholinergics and cognition in primary care older adults. METHODS: This cluster randomized clinical trial will be conducted to evaluate the impact of an anticholinergic deprescribing intervention compared to usual care on outcomes of cognition and safety in primary care older adults. Participants will include those aged 65 years and over, receiving primary care in the greater Indianapolis area, using a strong anticholinergic within the last 2 weeks or with evidence of high-risk exposure in the past year. Those excluded will have a diagnosis of Alzheimer's disease or related dementia, or serious mental illness. The trial plans to enroll 344 participants who will be cluster-randomized at the level of primary care physician to avoid contamination. Participants will complete outcome assessments every 6 months up to 2 years by blinded outcome assessors. The primary outcome of the study is a composite measure of cognition that includes domains assessing executive cognitive function, language, and memory. Secondary outcomes include patient-reported measures of pain intensity, depression, anxiety, sleep disturbance, and health-related quality of life. DISCUSSION: The R2D2 trial will be the largest and longest prospective randomized trial testing the impact of an anticholinergic-specific deprescribing intervention on cognition in primary care older adults. Results could influence deprescribing methodology and provide new insight on the relationship between anticholinergics and cognition. TRIAL REGISTRATION: ClinicalTrials.gov NCT04270474. Registered on February 17, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Campbell NL, Holden RJ, Gao S, et al. Deprescribing anticholinergics to preserve brain health: reducing the risk of dementia through deprescribing (R2D2): study protocol for a randomized clinical trial. Trials. 2024. PMID: 39578926. doi:10.1186/s13063-024-08618-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。